A Non Interventional Pilot Study on Machine Learning for ILD detection based on the patient data from digital devices in unresectable stage III Non-Small Cell Lung Cancer Patients receiving durvalumab

Trial Identifier: D4194R00024
Sponsor: AstraZeneca
NCTID:: NCT04884269
Start Date: August 2021
Primary Completion Date: March 2023
Study Completion Date: March 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Aichi Nagoya, Aichi, Japan, 464-8681
Japan, Aichi Nagoya, Aichi, Japan, 460-0001
Japan, Aichi Toyoake, Aichi, Japan, 470-1192
Japan, Ehime Matsuyama, Ehime, Japan, 791-0280
Japan, Fukuoka Fukuoka, Japan, 811-1395
Japan, Gunma Ota, Gunma, Japan, 373-8550
Japan, Hokkaido Sapporo, Hokkaido, Japan, 060-8648
Japan, Kanagawa Yokohama, Kanagawa, Japan, 236-0051
Japan, Kanagawa Yokohama, Kanagawa, Japan, 232-0024
Japan, Kanagawa Yokohama, Kanagawa, Japan, 241-8515
Japan, Mie Matsusaka, Mie, Japan, 515-8544
Japan, Miyagi Natori, Miyagi, Japan, 981-1293
Japan, Miyagi Sendai, Miyagi, Japan, 980-0873
Japan, Niigata Niigata, Japan, 951-8566
Japan, Okayama Kurashiki, Okayama, Japan, 710-8602
Japan, Okayama Okayama, Japan, 700-8558
Japan, Osaka Hirakata, Osaka, Japan, 573-1191
Japan, Osaka Osaka, Japan, 541-8567
Japan, Osaka Sakai, Osaka, Japan, 591-8555
Japan, Saitama Hidaka, Saitama, Japan, 350-1298
Japan, Saitama Kitaadachi-gun Ina, Saitama, Japan, 362-0806
Japan, Shizuoka Sunto-gun Nagaizumi, Shizuoka, Japan, 411-8777
Japan, Tokushima Tokushima, Japan, 770-8503
Japan, Tokyo Bunkyo, Tokyo, Japan, 113-8603
Japan, Tokyo Bunkyo, Tokyo, Japan, 113-8677
Japan, Tokyo Mitaka, Tokyo, Japan, 181-8611
Japan, Wakayama Wakayama, Japan, 641-8510